Corvus Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 8.45, 42.88, 83.89, 159.25 ], "ebit_estimate": [ -66.92, -82.81, -74.49, -38.88, 17.77 ], "ebitda_estimate": [ -58.65, -75.96, -90.49, null, null ], "net_income_estimate": [ -61.58, -78.45, -72.62, -37.01, 20.75 ], "per_share_eps_estimate": [ -0.69, -0.86, -0.63, -0.42, 0.13 ], "eps_nri_estimate": [ -0.68, -0.85, -0.75, -0.42, 0.13 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -61.95, -78.19, -72.86, -59.51, 20.24 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ 90, 93, 96, 98, 98 ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 117.82 ], "long_term_growth_rate_mean": -54.46, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -46.2, "future_eps_nri_estimate_growth": -54.46, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -20.48, "future_ebitda_estimate_growth": -28.4, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -63.52, "future_pretax_income_estimate_growth": -63.53, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -16.3, -17.76, -19.65, -20.57, -22.5, -23.65, -24.4 ], "ebitda_estimate": [ -14.29, -14.88, -17.28, -18.39, null, null, null ], "net_income_estimate": [ -15.52, -17.21, -19.07, -21.45, -22, -23.15, -23.9 ], "per_share_eps_estimate": [ -0.17, -0.19, -0.21, -0.24, -0.24, -0.26, -0.26 ], "eps_nri_estimate": [ -0.16, -0.17, -0.2, -0.22, -0.24, -0.26, -0.26 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -15.87, -17.71, -19.78, -23.4, -25, -25.8, -27.3 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -54.46, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -46.2, "future_eps_nri_estimate_growth": -54.46, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -20.48, "future_ebitda_estimate_growth": -28.4, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -63.52, "future_pretax_income_estimate_growth": -63.53, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }